Stronger cholesterol treatment shrinks more plaque in heart arteries, trial finds
Stronger cholesterol treatment shrinks more plaque in heart arteries, trial finds
Stronger cholesterol treatment shrinks more plaque in heart arteries, trial finds
Key points
اہم نکات
मुख्य बातें
- A stronger cholesterol-lowering treatment shrank more plaque in heart arteries than standard treatment, a new clinical trial has found, Medical Xpress reports.
- In the FLOWPROMOTE trial, 104 adults in Denmark with newly diagnosed heart disease took either atorvastatin alone or rosuvastatin plus ezetimibe for 18 months.
- The combination cut bad cholesterol by 65 percent, to 42.5 mg/dL, and total plaque shrank by 21.1 percent, compared with 13.6 percent on standard treatment.
- A stronger cholesterol-lowering treatment shrank more plaque in heart arteries than standard treatment, a new clinical trial has found, Medical Xpress reports.
- In the FLOWPROMOTE trial, 104 adults in Denmark with newly diagnosed heart disease took either atorvastatin alone or rosuvastatin plus ezetimibe for 18 months.
- The combination cut bad cholesterol by 65 percent, to 42.5 mg/dL, and total plaque shrank by 21.1 percent, compared with 13.6 percent on standard treatment.
- A stronger cholesterol-lowering treatment shrank more plaque in heart arteries than standard treatment, a new clinical trial has found, Medical Xpress reports.
- In the FLOWPROMOTE trial, 104 adults in Denmark with newly diagnosed heart disease took either atorvastatin alone or rosuvastatin plus ezetimibe for 18 months.
- The combination cut bad cholesterol by 65 percent, to 42.5 mg/dL, and total plaque shrank by 21.1 percent, compared with 13.6 percent on standard treatment.
A stronger cholesterol-lowering treatment shrank more plaque in heart arteries than standard treatment, a new clinical trial has found, Medical Xpress reports. In the FLOWPROMOTE trial, 104 adults in Denmark with newly diagnosed heart disease took either atorvastatin alone or rosuvastatin plus ezetimibe for 18 months. The combination cut bad cholesterol by 65 percent, to 42.5 mg/dL, and total plaque shrank by 21.1 percent, compared with 13.6 percent on standard treatment. Plaque shrank in 90 percent of patients on the combination. The researchers say more work is needed to show whether the extra shrinkage prevents heart attacks.
A stronger cholesterol-lowering treatment shrank more plaque in heart arteries than standard treatment, a new clinical trial has found, Medical Xpress reports. In the FLOWPROMOTE trial, 104 adults in Denmark with newly diagnosed heart disease took either atorvastatin alone or rosuvastatin plus ezetimibe for 18 months. The combination cut bad cholesterol by 65 percent, to 42.5 mg/dL, and total plaque shrank by 21.1 percent, compared with 13.6 percent on standard treatment. Plaque shrank in 90 percent of patients on the combination. The researchers say more work is needed to show whether the extra shrinkage prevents heart attacks.
A stronger cholesterol-lowering treatment shrank more plaque in heart arteries than standard treatment, a new clinical trial has found, Medical Xpress reports. In the FLOWPROMOTE trial, 104 adults in Denmark with newly diagnosed heart disease took either atorvastatin alone or rosuvastatin plus ezetimibe for 18 months. The combination cut bad cholesterol by 65 percent, to 42.5 mg/dL, and total plaque shrank by 21.1 percent, compared with 13.6 percent on standard treatment. Plaque shrank in 90 percent of patients on the combination. The researchers say more work is needed to show whether the extra shrinkage prevents heart attacks.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।